+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cardiac Marker Market (2021-2026) by Type, Components, Location of Testing, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 185 Pages
  • June 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5410402
The Global Cardiac Marker Market is estimated to be USD 3.2 Bn in 2021 and is expected to reach USD 4.95 Bn by 2026, growing at a CAGR of 9.1%.



Market Dynamics

The factors such as the rise in prevalence of cardiac diseases, unique features of a cardiac biomarker such as high accuracy, quick outcomes, and economical pricing of cardiac point of care (POC) testing are driving the market. Additionally, the growing awareness among patients and healthcare providers about the importance of early diagnosis and care of various CVDs is driving the demand for cardiac markers. The rise in investment in research and the development of advanced technologies in the field of novel cardiac biomarkers and personalized medicine is expected to create lucrative opportunities for the growth of the market.

However, Technical issues related to the sample collection and storage and the high cost involved in cardiac marker testing are expected to hamper the market growth.

Market Segmentation

The Global Cardiac Marker Market is segmented further based on Type, Components, Location of Testing, Application, and Geography.

By Type, the market is classified into Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Natriuretic Peptides (BNP, NT-proBNP), High-sensitivity C-reactive Protein (hs-CRP), and Others. Amongst all, the Troponins (T and I) segment is estimated to hold the highest market share during the forecast period.

By Components, the market is classified as Reagents & Kits and Instruments. Amongst the two, the Instruments segment is estimated to hold the highest market share during the forecast period.

By Location of Testing, the market is classified as Laboratory Testing and Point of Care Testing. Amongst all, the Laboratory Testing segment is estimated to hold the highest market share during the forecast period.

By Application, the market is classified into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others. Amongst all, the Myocardial Infarction segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment. - 28th April 2021

Company Profiles

Some of the companies covered in this report are Abbott Laboratories, Beckman Coulter, Inc. bioMérieux SA, Johnson and Johnson, Olympus Corporation, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cardiac Marker Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cardiac Marker Market

What is the estimated value of the Global Cardiac Marker Market?

The Global Cardiac Marker Market was estimated to be valued at $3200 Million in 2021.

What is the growth rate of the Global Cardiac Marker Market?

The growth rate of the Global Cardiac Marker Market is 9.1%, with an estimated value of $4950 Million by 2026.

What is the forecasted size of the Global Cardiac Marker Market?

The Global Cardiac Marker Market is estimated to be worth $4950 Million by 2026.

Who are the key companies in the Global Cardiac Marker Market?

Key companies in the Global Cardiac Marker Market include Abbott Laboratories, Advanced ImmunoChemical, AgPlus Diagnostics Ltd, Alere Inc, Beckman Coulter, Inc., Becton Dickinson and Company, BG Medicine, BioLegend and Bio.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Prevalence of Cardiovascular Diseases
4.1.2 Development of Highly Sensitive Biomarkers
4.1.3 Raising Awareness of Point-Of-Care Testing (POCT)
4.1.4 Rapid Growth of the Geriatric Population
4.2 Restraints
4.2.1 Technical Issues Related to Sample Collection and Storage
4.2.2 Strict Government Regulations
4.3 Opportunities
4.3.1 Penetration of Personalized Medicine and Novel Cardiac Biomarkers in Emerging Markets
4.3.2 Technological Advancements in the Cardiac Markers
4.4 Challenges
4.4.1 Complex Process and Lack of Skilled Personnel
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Cardiac Marker Market, By Type
6.1 Introduction
6.2 Myocardial Muscle Creatine Kinase (CK-MB)
6.3 Troponins (T and I)
6.4 Myoglobin
6.5 Natriuretic Peptides (BNP, NT-proBNP)
6.6 High-sensitivity C-reactive Protein (hs-CRP)
6.7 Others
7 Global Cardiac Marker Market, By Components
7.1 Introduction
7.2 Reagents & Kits
7.3 Instruments
7.3.1 Chemiluminescence
7.3.2 Immunofluorescence
7.3.3 ELISA
7.3.4 Immunochromatography
8 Global Cardiac Marker Market, By Location of Testing
8.1 Introduction
8.2 Laboratory Testing
8.3 Point of Care Testing
9 Global Cardiac Marker Market, By Application
9.1 Introduction
9.2 Myocardial Infarction
9.3 Congestive Heart Failure
9.4 Acute Coronary Syndrome
9.5 Atherosclerosis
9.6 Others
10 Global Cardiac Marker Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 Abbott Laboratories
12.2 Advanced ImmunoChemical
12.3 AgPlus Diagnostics Ltd
12.4 Alere Inc
12.5 Beckman Coulter, Inc.
12.6 Becton Dickinson and Company
12.7 BG Medicine
12.8 BioLegend
12.9 BioMerieux, Inc.
12.10 Bio-Rad Laboratories, Inc.
12.11 Boditech Med Inc
12.12 Danaher Corporation
12.13 F. Hoffmann-La Roche Ltd.
12.14 Guangzhou Wondfo Biotech Co., Ltd
12.15 Johnson and Johnson
12.16 LSI Medience Corporation
12.17 Ortho Clinical Diagnostics
12.18 Olympus Corporation
12.19 PerkinElmer Inc.
12.20 Randox Laboratories Ltd.
12.21 Roche Diagnostics Corporation
12.22 Siemens Healthcare
12.23 Siemens AG
12.24 Thermo Fisher Scientific
12.25 Tosoh Corporation
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Advanced ImmunoChemical
  • AgPlus Diagnostics Ltd
  • Alere Inc
  • Beckman Coulter, Inc.
  • Becton Dickinson and Company
  • BG Medicine
  • BioLegend
  • BioMerieux, Inc.
  • Bio-Rad Laboratories, Inc.
  • Boditech Med Inc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guangzhou Wondfo Biotech Co., Ltd
  • Johnson and Johnson
  • LSI Medience Corporation
  • Ortho Clinical Diagnostics
  • Olympus Corporation
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Roche Diagnostics Corporation
  • Siemens Healthcare
  • Siemens AG
  • Thermo Fisher Scientific
  • Tosoh Corporation